PresentationAlexander Siedler Hello. Good morning and good afternoon, everybody, and welcome to our investor webinar on the results of the OCEANIC-STROKE Phase III trial directly live from ISC 2026 in New Orleans. So my name is Alex Siedler. I'm with the Bayer Investor Relations Department, and I'm joined by 3 fine young men with me today. So very much looking forward to being with you for the next hour. And the gentlemen are Christoph Koenen, our Head of Clinical Development and Operations at Bayer. He wil ...

Key Takeaways Bayer's phase III OCEANIC-STROKE trial showed asundexian cut recurrent ischemic stroke risk by 26%.BAYRY said the drug met safety goals, with no increase in major bleeding versus placebo.Bayer plans to submit the data for approval, strengthening its cardiovascular pipeline and growth outlook.Bayer (BAYRY) presented positive results from the late-stage OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, factor XIa inhibitor asundexian (50mg) compared to placebo, bo ...

NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared to placebo, both in combination with antiplatelet therapy. Asundexian significantly reduced ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p ...

经济观察网国家药品监督管理局(NMPA)正式批准口服新型雄激素受体抑制剂(ARi)诺倍戈(达罗他胺片) 联合雄激素剥夺疗法(ADT)治疗转移性激素敏感性前列腺癌(mHSPC)成年患者。诺倍戈此前已先后获批 用于治疗有高危转移风险的非转移性去势抵抗性前列腺癌(NM-CRPC)成年患者，和联合多西他赛治疗 转移性激素敏感性前列腺癌的(mHSPC)成年患者。此次获批是诺倍戈的第三项适应症。 ...

红杉中国是在"抄底"一个被巨头剥离的现金牛业务，还是在下一盘更大的棋？被誉为"呼吸科神药"的拜 复乐，能否在金肖东的手中迎来"第二春"？ 01 "反常"的红杉与"没落"的贵族 2月2日的医药圈，被一则看似"反常"的收购案搅动了。 一向以投资"高精尖"创新药和前沿生物科技闻名的顶级VC红杉中国，突然调转船头，宣布完成对一款 经典抗生素莫西沙星（商品名：拜复乐/Avelox）相关业务的全球收购。 为了承接这项庞大的全球资产，红杉同步成立了全新的生物医药平台杭州杉泽生物医药有限公司（以下 简称"杉泽生物"）及其母公司Ascenda Pte.Ltd.。 这笔交易的标的物，是德国制药巨头拜耳旗下曾经的"重磅炸弹"级药物，一款在全球年治疗患者超过 2.4亿的广谱抗生素。根据协议，杉泽生物拿下了拜复乐在全球范围内的药品注册证、知识产权及业务 合同等核心资产使其成为一家由投资机构100%控股的全球性医药资产。 当VC开始做起PE的活，收购一个"昨日黄花"的成熟药品，这背后显然不是一次简单的财务投资。红杉 的动作迅速且精准，为这个新平台请来了一位重量级舵手金肖东。 这位履历横跨多家跨国药企与本土生物医药企业的资深高管，上一站是 ...

《共识》中提到："复方口服避孕药（combined oral contraceptives，COC）是目前全球范围广泛使 用的高效避孕方法之一……目前，COC在我国育龄期妇女中的使用率非常低，出于对激素类药物的恐 惧心理，对COC的了解不足或存在偏见，是我国COC使用率甚低的主要原因之一。"这种认知差距，使 得许多女性未能充分利用这类可同时提供避孕与非避孕健康获益（如治疗中度痤疮）的科学方案。 复旦大学附属妇产科医院史颖莉教授说："对于临床诊断明确、治疗方案稳定、需长期药物支持的 慢性病患者，经专业医生评估后可开具长处方。避孕及痤疮治疗均需在医师指导下长期规范用药，一旦 因购药不及时而中断，往往会影响疗效。优思悦®84片装的推出，有助于减少频繁购药和不当停药的情 况，提升患者依从性和用药连续性，为临床实践和患者管理提供了更为便利的选择。" 优思悦®（屈螺酮炔雌醇片Ⅱ）是一种短效口服避孕药，2014年12月份在中国获批上市，是中国首 个采用"24+4"给药模式的复方口服避孕药，24片活性药片（每片含0.02mg炔雌醇和3mg屈螺酮）加4片 无活性药片，适用于女性避孕，及≥14岁、没有口服避孕药已知禁忌的已初潮女 ...

与此同时，《复方口服避孕药临床应用中国专家共识》（以下简称《共识》）解读活动也正式启动，聚 焦疾病长程管理，旨在提升女性对用药依从性在疾病管理中关键作用的认知。 本报讯 （记者袁传玺）1月29日，拜耳原研口服避孕药优思悦 84片装大包装首批药品顺利完成进口通 关，率先在阿里健康首发，该规格于第八届中国国际进口博览会首次亮相，旨在覆盖三个月完整的用药 周期，提升用药的便利性和依从性，更好地契合女性健康长周期管理的实际需求。 《共识》中提到："复方口服避孕药（combined oral contraceptives，COC）是目前全球范围广泛使用的 高效避孕方法之一……目前，COC在我国育龄期妇女中的使用率非常低，出于对激素类药物的恐惧心 理，对COC的了解不足或存在偏见，是我国COC使用率甚低的主要原因之一。"这种认知差距，使得许 多女性未能充分利用这类可同时提供避孕与非避孕健康获益（如治疗中度痤疮）的科学方案。 复旦大学附属妇产科医院史颖莉教授说："对于临床诊断明确、治疗方案稳定、需长期药物支持的慢性 病患者，经专业医生评估后可开具长处方。避孕及痤疮治疗均需在医师指导下长期规范用药，一旦因购 药不及时而中断， ...

CALGARY, Alberta--(BUSINESS WIRE)--Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada's leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located in Winnipeg, Manitoba, the facility will house seed development work for canola, camelina and winter canola, focusing on trait integration, yield trial seed processing and seed quality analysis. "A long-term strategic investment of this scale demonstrates Bayer's. ...

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores provide a framework for evaluating stocks based on value, growth, and momentum, aiding investors in selecting securities likely to outperform the market [2] Zacks Style Scores Overview - Stocks are rated A, B, C, D, or F based on their value, growth, and momentum characteristics, with higher scores indicating a better chance of outperforming the market [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - The Value Style Score focuses on identifying undervalued stocks using metrics like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Style Score assesses a company's financial health and future outlook through projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Style Score evaluates trends in stock prices and earnings estimates to identify favorable buying opportunities [5] VGM Score - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors seeking attractive value, growth, and momentum [6] Zacks Rank Integration - The Zacks Rank utilizes earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7] - There are over 800 stocks rated 1 or 2, making it essential for investors to utilize Style Scores to narrow down choices [8] Investment Strategy - For optimal returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while 3 ranked stocks should also have high Style Scores to maximize upside potential [9][10] Company Spotlight: Bayer Aktiengesellschaft - Bayer AG, headquartered in Leverkusen, Germany, is rated 2 (Buy) on the Zacks Rank with a VGM Score of A and a Value Style Score of A, indicating strong valuation metrics [11] - The company has seen two analysts raise their earnings estimates for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.10 to $1.43 per share and an average earnings surprise of +18.5% [12]

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...